Exploring Quality Measures for the Care of Transgender Persons
Exploring Quality Measures for the Care of Transgender Persons
批准号:
9436471
负责人:
Guneet K. Jasuja
金额:
$27.85万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-20 至 2019-04-30
关键词:
AdultAgeCaringClinicalClinical DataClinical Practice GuidelineCodeCollectionComputerized Medical RecordDataData SetData SourcesDatabasesDevelopmentDiagnosisDiscriminationElementsEligibility DeterminationEnsureExogenous Hormone TherapyFemaleFeminizationFoundationsFutureGenderGender IdentityGoalsGuidelinesHealthHealthcareIndividualInpatientsInsuranceKnowledgeLaboratoriesMasculineMeasuresMedicineMethodsMonitorNatureOutpatientsPatient CarePatientsPersonsPharmacy facilityPhysiciansPopulationProceduresProcessProviderPublished CommentQuality of CareRaceReportingResearchResearch PersonnelSamplingSubgroupTestingTimeUnited StatesUnited States National Institutes of HealthValidity and Reliabilitybasecandidate validationdisparity reductionexperiencegender dysphoriahealth care deliveryhealth disparityhormone therapyimprovedinnovationmalemembermethod developmentpatient populationservice utilizationsocial stigmatransgender
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Background: Transgender adults (“trans persons”) comprise 0.6% of the United States population. The few
studies that have characterized the care received by trans persons have used relatively small and non-
representative samples. There is a need to know more about the care that trans persons currently receive, as
a basis for improving this care in the future.
Approach: We will use a database containing approximately 160 million people, which is broadly representative
of commercially insured people in the United States. In our pilot analyses, we identified 9,632 trans persons in
this database, based solely upon diagnosis codes for gender dysphoria. Our project will have three aims. First,
we will use a more comprehensive approach to identify trans persons in the dataset, including additional
diagnosis codes, procedure codes, prescription fills, and inconsistencies in the gender variable. Second,
having identified a population of trans persons, we will characterize the care they receive. We have identified
four prominent clinical practice guidelines for trans care. Using these guidelines, we will identify important
aspects of transgender care that are amenable to being characterized using a large database. As an example,
we will characterize the adequacy of laboratory monitoring in patients receiving transgender hormone therapy.
We have already identified at least fourteen aspects of care to study. In finalizing our list of analyses, and
operationalizing how we will analyze them, we will be advised by a panel of clinical experts. For each analysis,
we will define a denominator, or a group of patients eligible to receive that care element, and a numerator, a
subset of the denominator who did receive it. We will calculate the proportion of patients who received each
care element, and examine differences between subgroups (e.g., male vs. female gender identity, age, race).
Third, we will convene a panel of seven clinical experts in trans care, as well as three trans patients. Using our
results, this technical expert panel (TEP) will help advise us regarding which analyses would be potentially
suitable to serve as a basis for developing quality of care metrics for trans patients. TEP members will be
asked to comment on four aspects of potential quality measures: 1) importance; 2) reliability and validity; 3)
ease of understanding; and 4) feasibility of collection and calculation.
Anticipated Impacts: This study will constitute the largest study to characterize the care delivered to trans
persons to date, and the results will be generalizable to the US population of commercially insured individuals.
The methods we develop to identify trans persons in a large, automated database will serve as a basis for
future studies by our group and by others. In addition to providing a baseline for the quality of care delivered to
trans persons today, our results and the input from our TEP will provide a basis for the future development of
quality measures for trans care. The existence of such quality measures has the potential to facilitate quality
improvement over time.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: